Zahra Rezaeian - Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Fatemeh Abedini - Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Saeedeh Arabzadeh - Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Maryam Farzan - Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Mehran Sharifi - Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Amirreza Manteghinejad - Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Background: Patients with multiple myeloma (MM) have compromised immune systems due to the nature of the malignancy and anticancer treatments. This study aims to report the effects of Bortezomib-containing chemotherapy regimens on the severity and mortality of MM patients infected with severe acute respiratory syndrome coronavirus ۲ (SARS-COV-۲). Method: This retrospective cohort study enrolled MM patients presenting with coronavirus disease ۲۰۱۹ (COVID-۱۹) infection referred to Omid Hospital. Patients were divided into two groups based on whether they received any chemotherapy regimens containing Bortezomib within the last ۹۰ days of admission or not. Clinical and laboratory characteristics, severity, and outcomes of both groups were reported and compared. Results: Among ۴۸ patients with MM diagnosed with COVID-۱۹ (۶۳% male; median age ۶۶), ۳۳ received chemotherapy. The most common symptoms were fever, cough, and dyspnea, and there was no significant difference between the groups. Only D-dimer had a significant difference in laboratory tests (P = ۰.۰۳) and was higher in the chemotherapy group. There was no significant relationship between chemotherapy and severity (risk ratio (RR) = ۱.۱۷; ۹۵% confidence interval (CI): ۰.۳۷ to ۳.۷۱; P = ۰.۷۹) or chemotherapy and mortality (RR= ۱.۰۰; ۹۵% CI: ۰.۳۹ to ۲.۶۱; P = ۰.۹۹), even after adjusting for baseline C-reactive protein and white blood cell counts. Conclusion: Our study showed that receiving Bortezomib-containing chemotherapy regimens did not worsen the symptoms and prognosis of MM patients infected with COVID-۱۹. However, further studies with larger sample sizes and longer follow-up times are needed to provide better evidence on this subject.

COVID-۱۹, cancer, Hematologic Neoplasms, Multiple myeloma, Bortezomib